| Identification of ALK as a major familial neuroblastoma predisposition gene YP Mossé, M Laudenslager, L Longo, KA Cole, A Wood, EF Attiyeh, ... Nature 455 (7215), 930-935, 2008 | 1662 | 2008 |
| Dissecting the genomic complexity underlying medulloblastoma DTW Jones, N Jäger, M Kool, T Zichner, B Hutter, M Sultan, YJ Cho, ... Nature 488 (7409), 100-105, 2012 | 952 | 2012 |
| Comparison of RNA-seq and microarray-based models for clinical endpoint prediction W Zhang, Y Yu, F Hertwig, J Thierry-Mieg, W Zhang, D Thierry-Mieg, ... Genome biology 16, 1-12, 2015 | 402 | 2015 |
| Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients I Casciano, K Mazzocco, L Boni, G Pagnan, B Banelli, G Allemanni, ... Cell Death & Differentiation 9 (3), 246-251, 2002 | 264 | 2002 |
| Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients L Passoni, L Longo, P Collini, AML Coluccia, F Bozzi, M Podda, ... Cancer research 69 (18), 7338-7346, 2009 | 214 | 2009 |
| Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group … B De Bernardi, B Nicolas, L Boni, P Indolfi, M Carli, ... Journal of clinical oncology 21 (8), 1592-1601, 2003 | 202 | 2003 |
| Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study J Vermeulen, K De Preter, A Naranjo, L Vercruysse, N Van Roy, ... The lancet oncology 10 (7), 663-671, 2009 | 195 | 2009 |
| Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project G Schleiermacher, V Mosseri, WB London, JM Maris, GM Brodeur, ... British journal of cancer 107 (8), 1418-1422, 2012 | 190 | 2012 |
| Retrospective study of childhood ganglioneuroma B De Bernardi, C Gambini, R Haupt, C Granata, A Rizzo, M Conte, ... Journal of Clinical Oncology 26 (10), 1710-1716, 2008 | 165 | 2008 |
| Prognostic impact of gene expression–based classification for neuroblastoma A Oberthuer, B Hero, F Berthold, D Juraeva, A Faldum, Y Kahlert, ... Journal of Clinical Oncology 28 (21), 3506-3515, 2010 | 143 | 2010 |
| Quality assessment of genetic markers used for therapy stratification IM Ambros, J Benard, M Boavida, N Bown, H Caron, V Combaret, ... Journal of clinical oncology 21 (11), 2077-2084, 2003 | 142 | 2003 |
| MYCN On cogene Amplification in Neuroblastom a Is Associated VVith VVorse Prognosis, Except in Stage 4s: The Italian Experience VVith 295 Children GP Tonini, L Boni, A Pession, D Rogers Journal of clinical oncology 15 (1), 85-93, 1997 | 138 | 1997 |
| Neuroblastoma (Peripheral neuroblastic tumours) R Luksch, MR Castellani, P Collini, B De Bernardi, M Conte, C Gambini, ... Critical reviews in oncology/hematology 107, 163-181, 2016 | 132 | 2016 |
| Transcribed-ultra conserved region expression is associated with outcome in high-risk neuroblastoma P Scaruffi, S Stigliani, S Moretti, S Coco, C De Vecchi, F Valdora, ... BMC cancer 9, 1-9, 2009 | 130 | 2009 |
| Neuroblastoma treatment in the post-genomic era MR Esposito, S Aveic, A Seydel, GP Tonini Journal of biomedical science 24, 1-16, 2017 | 125 | 2017 |
| Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on … M Capasso, SJ Diskin, F Totaro, L Longo, MD Mariano, R Russo, ... Carcinogenesis 34 (3), 605-611, 2013 | 123 | 2013 |
| Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative … G Schleiermacher, J Michon, A Ribeiro, G Pierron, V Mosseri, H Rubie, ... British journal of cancer 105 (12), 1940-1948, 2011 | 111 | 2011 |
| Genomic amplifications and distal 6q loss: novel markers for poor survival in high-risk neuroblastoma patients P Depuydt, V Boeva, TD Hocking, R Cannoodt, IM Ambros, PF Ambros, ... JNCI: Journal of the National Cancer Institute 110 (10), 1084-1093, 2018 | 98 | 2018 |
| Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression VA Lasorsa, D Formicola, P Pignataro, F Cimmino, FM Calabrese, J Mora, ... Oncotarget 7 (16), 21840, 2016 | 97 | 2016 |
| Revised risk estimation and treatment stratification of low-and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers A Oberthuer, D Juraeva, B Hero, R Volland, C Sterz, R Schmidt, A Faldum, ... Clinical Cancer Research 21 (8), 1904-1915, 2015 | 96 | 2015 |
achille iolasconAffiliazione Dept of Molecular Medicine and Medical Biotechnology在 unina.it 的电子邮件经过验证
